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CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) loci and 1 
their associated (cas) genes encode an adaptive immune system that protects 2 
prokaryotes from viral1 and plasmid2 invaders. Upon viral (phage) infection, a 3 
small fraction of the prokaryotic cells are able to integrate a small sequence of 4 
the invader’s genome into the CRISPR array1. These sequences, known as 5 
spacers, are transcribed and processed into small CRISPR RNA (crRNA) guides3-5 6 
that associate with Cas nucleases to specify a viral target for destruction6-9. 7 
Although, CRISPR-cas loci are widely distributed throughout microbial genomes 8 
and often display hallmarks of horizontal gene transfer10-12, the drivers of CRISPR 9 
dissemination remain unclear. Here we show that spacers can recombine with 10 
phage target sequences to mediate a form of specialized transduction of CRISPR 11 
elements. Phage targets in phage 85, ΦNM1, ΦNM4, and Φ12 can recombine with 12 
spacers in either chromosomal or plasmid-borne CRISPR loci in Staphylococcus, 13 
leading to either the transfer of CRISPR-adjacent genes or the propagation of 14 
acquired immunity to other bacteria in the population, respectively. Our data 15 
demonstrate that spacer sequences not only specify the targets of Cas 16 
nucleases, but also can promote horizontal gene transfer. 17 
Bioinformatic analysis of CRISPR-cas loci have uncovered hallmarks of horizontal gene 18 
transfer (HGT)10-12 and CRISPR-Cas modularity13-15. Phylogenies based on either 19 
CRISPR repeats or the universal Cas1 protein revealed poor correlations between 20 
bacterial species trees, suggesting evidence of HGT of CRISPR-cas loci between 21 
distantly related bacterial species16-18. Furthermore, genomic studies have suggested 22 
that CRISPR systems evolved from a common ancestor and co-opted a diverse set of 23 
effector modules, potentially via HGT13-15.  Plasmid conjugation16,18,19 and 24 
  
bacteriophage transduction20, fundamental routes for HGT21, have been implicated in 25 
the dissemination of CRISPR-cas loci22. Transduction occurs during viral infection, and 26 
can be divided into generalized or specialized23. Generalized transduction is a rare 27 
event that occurs when the phage machinery packages any DNA from the infected 28 
(donor) cell and subsequently delivers this DNA into a recipient cell. It is mediated by 29 
pac but not cos phages. In contrast, specialized transduction is a more specific event 30 
mediated by prophages (both pac and cos) that package genes located in the vicinity of 31 
their integration site. Recently it was shown that the type I-F CRISPR-cas locus of 32 
Pectobacterium atrosepticum can be mobilized through generalized transduction at 33 
rates ~10-8 (ref. 22). Here we sought to determine if specific mechanisms are in place to 34 
mediate a more efficient horizontal gene transfer of CRISPR-Cas systems, their 35 
components, or their flanking sequences. 36 
We explored whether recombination between newly acquired spacers and their targeted 37 
phage could mediate transduction. It is well established that even short sequences with 38 
homology to a phage leads to recombination events that integrate the homologous DNA 39 
into the viral genome, leading to a drastic enhancement of the transduction rates of 40 
plasmids24-27, for example. The acquisition of a 30-40 bp spacer sequence from the 41 
infecting virus during the CRISPR-Cas adaptive immune response would introduce 42 
homology between the phage genome and the CRISPR locus, and could facilitate 43 
recombination and elevated rates of transduction. Such mechanism would lead to the 44 
transduction of genes adjacent to the CRISPR locus (Fig. 1A). To test this, we added an 45 
erythromycin resistance gene adjacent to the chromosomal type III-A system within the 46 
methicillin resistance cassette (SCCmec) of Staphylococcus aureus 08BA0217628, and 47 
inserted a target site for the first spacer of this CRISPR locus at two locations (P1 and 48 
  
P2) of the staphylococcal phage 85 genome29, or a new spacer (C1) matching orf28 49 
(Fig S1A). This erythromycin-resistant strain was infected with each of the three phages 50 
or a non-targeted, wild-type phage as a control, and the lysates were used to transduce 51 
the marker into the wild-type strain. We observed that spacers P1 and C1 enhanced 52 
transduction of the antibiotic resistance cassette by one order of magnitude over the 53 
non-targeting control (Fig. 1B). Since there are no differences in the viability of the 54 
recipient cells (Fig. S1B), these results suggest that recombination between spacers P1 55 
and C1 and the phages harboring their targets can direct the transfer of genomic 56 
locations adjacent to the CRISPR locus at rates that exceed those observed for 57 
generalized transduction (mediated by the non-targeted control phage). We also 58 
investigated the possibility of spacer-mediated transduction of entire chromosomal 59 
CRISPR-cas loci to CRISPR-lacking strains. Using two different empirical systems, the 60 
type I-F CRISPR-Cas system of Pseudomonas aeruginosa and the DMS3vir phage30 61 
and the type II-A CRISPR-Cas system of Streptococcus thermophilus and the 2972 62 
phage1, with adjacent chromosomal markers to track transduction (Fig. S1C), we 63 
observed generalized but not spacer-mediated transduction of the entire CRISPR-Cas 64 
system (Fig. S1D,E). Most likely this is a result of the presence of only one region of 65 
homology for integration (Fig. S1C). 66 
Although most CRISPR-Cas systems reside on chromosomes, an important fraction of 67 
CRISPR loci has been reported to be carried on plasmids31. Plasmid-borne CRISPR loci 68 
offer unique advantages for their lateral transfer via spacer recombination: the 69 
increased copy number elevates the probability of recombination27,32 and the circular 70 
nature allows the insertion of the entire CRISPR-cas locus into the phage genome, 71 
facilitating its packaging and re-circularization into the recipient host (Fig. 1C). To 72 
  
explore this, we first tested if the transduction of CRISPR-carrying plasmids can be 73 
mediated by the newly acquired spacers. We infected S. aureus RN422033 cells (which 74 
lack endogenous CRISPR-cas loci) carrying the type II-A locus of Streptococcus 75 
pyogenes5 (Fig. S2A) into the 2.9 kb staphylococcal plasmid pC194 (pCRISPR, 76 
conferring chloramphenicol resistance), with a staphylococcal pac phage carrying a 77 
virulent mutation, ΦNM4γ433. Staphylococci harboring pCRISPR, but not an empty 78 
vector control, recovered at 12 hours (Fig. 1D) through the acquisition of new spacers 79 
(Fig. S2B), at the same time as the phage titers began to decline (Fig. 1D). We then 80 
checked for the presence of pCRISPR-transducing particles in phage filtrates (which 81 
also contain infective phages) by infecting S. aureus RN4220 recipients and selecting 82 
for chloramphenicol-resistant colonies. We detected an increase to a frequency of 1 83 
transduced colony per 104 plaque forming units in filtrates collected 16 hours post-84 
infection (Figs. 1D and S2C-F). In the type II-A CRISPR-Cas immune response, only a 85 
small fraction of cells acquires new spacers, the majority are not able to adapt and 86 
succumb to phage infection. To determine if transduction could transfer expanded 87 
pCRISPR loci to non-adapted cells, we mixed pCRISPR-harboring cells 88 
(chloramphenicol-resistant) and phage-sensitive recipients (kanamycin- and 89 
erythromycin-resistant) at a 1:5 ratio and infected with ΦNM4γ4. We were able to 90 
recover transduced colonies (resistant to all three antibiotics) at a frequency of ~ 10-5 91 
with respect to CRISPR-adapted colonies (chloramphenicol-resistant) (Figs. 1E and 92 
S2G). Altogether, the data presented in Figs. 1 and S2 demonstrate that CRISPR-Cas 93 
plasmids can spread to naïve cells through transduction during the course of the 94 
CRISPR-Cas immune response. 95 
  
Next, we investigated whether this transduction requires the presence acquired 96 
spacers, as it seems to be the case for the transduction of chromosomal CRISPR-97 
adjacent loci (Figs. 1AB). First, we compared the spacer repertoires of CRISPR-98 
resistant and CRISPR-transduced cells, obtained from the experiment in Figure 1E, 99 
using next-generation sequencing. Spacer sequences from four biological replicates 100 
were mapped onto the ΦNM4γ4 genome and plotted against their average number of 101 
reads (Fig. 2A, Supplementary Data File 1). The relative frequency of transduced 102 
spacers was consistent in each experiment (Fig. S3A) and we did not detect a 103 
correlation between the frequency of spacer acquisition and transduction (Fig. S3B and 104 
S3C). Instead, we found that spacers present in CRISPR-transduced cells were 105 
enriched in the 20-30 kb region of the phage, and depleted from the immediately 106 
preceding 5-20 kb region (Fig. 2A). These results suggest that there are CRISPR-cas 107 
loci containing specific spacer sequences that favor or limit their transduction. To test 108 
this we selected four spacer sequences, two with high (H1, H2), one with intermediate 109 
(I), and one with low (L) transduced/resistant ratio (Fig. 2A). These spacers were cloned 110 
into pCas9, a pCRISPR derivative unable to support new spacer acquisition due to the 111 
absence of cas1, cas2 and csn233. After infection with ΦNM4γ4, the populations 112 
carrying the high transducer spacers (H1 and H2) produced approximately three orders 113 
of magnitude more transducers than populations carrying the intermediate (I) or low (L)-114 
transducing spacers (Fig. 2B). These results indicate that the sequence of the acquired 115 
spacer determines the frequency of transduction of the CRISPR-cas locus which 116 
harbors it. Similar results were obtained with a plasmid-borne type III-A system, which 117 
displayed enhanced levels of transduction when the system contains a spacer matching 118 
the infecting phage genome (Figs. S4AB). 119 
  
To test if the spacer sequence itself could impact transduction we generated pSpacer 120 
plasmids containing only a repeat-spacer (H1, H2, I or L)-repeat unit, without cas9. After 121 
infection with ΦNM4γ4, we found that all four spacers equally increased the rate of 122 
pSpacer transfer when compared to a CRISPR array containing a control spacer that 123 
does not match the phage genome (Fig. 2C), suggesting that Cas9 targeting impacts 124 
the rate of transduction. Indeed, if pCRISPR transduction occurs through the formation 125 
of recombinants between the acquired spacer and the phage protospacer sequence, 126 
these recombinants will maintain a full target in one of the recombination junctions (Fig. 127 
S4C) which could be cleaved by Cas9. To investigate this, staphylococci carrying the 128 
pSpacer or pCas9 plasmids were infected with ΦNM4γ4 and DNA was isolated from 129 
bacterial pellets (containing infected cells) or culture supernatants (containing virions) 130 
for PCR amplification of both recombination junctions (Fig. 2D) as well as chromosomal 131 
and viral genes as controls for the fractionation (Fig. S4D). pSpacer/phage 132 
recombinants were detected at both junctions, for all spacer sequences, both in infected 133 
cells and virions, a result that explains the equal transduction levels of these plasmids 134 
(Fig. 2C). In contrast, pCas9/phage recombinants were also detected but PCR products 135 
were much less abundant for the targeted junction (J2) in infected cells (Fig. 2D). In 136 
virions, we only detected the non-targeted junction (J1) for the constructs containing H1 137 
and H2 spacers, along with a faint PCR product for the I-spacer construct; but we were 138 
unable to detect the PAM-flanked (J2) junction (Fig. 2D). These results were 139 
corroborated by next-generation sequencing of DNA extracted from the virion fraction 140 
after infection of cells containing pCas9(H1). We found abundant reads spanning the 141 
non-targeted phage-CRISPR junction (J1) were detected (Fig. 2E), while the targeted 142 
junction (J2) had relatively fewer reads (Fig. 2F). Altogether, these experiments 143 
  
demonstrate two important aspects of spacer-mediated recombination. First, 144 
recombination between the spacer sequence in pCRISPR and the protospacer 145 
sequence in ΦNM4γ4 results in the formation of hybrid DNA molecules which can be 146 
encapsidated into virions during infection. This does not depend on the host recA (Fig. 147 
S5A) and can also occur via the staphylococcal cos phage Φ12 (Fig. S5B). Second, 148 
Cas9 targeting of the PAM-flanked spacer/protospacer junction within these molecules 149 
reduces the efficacy of their packaging into viral capsids and therefore the efficiency of 150 
transduction. 151 
The presence of phage particles containing spacer/phage recombinants from infected 152 
CRISPR-immune cells suggests that incomplete protection of the host allows for the 153 
formation and release of the CRISPR-containing virions. Inefficient CRISPR immunity 154 
can be the result from at least two scenarios. One possibility is that the immunity 155 
provided by the acquired spacer can be bypassed by phages containing target 156 
mutations, known as "escapers”; in this case the spacers that target regions with high 157 
rate of mutation in the phage genome will be more prone to transduction. However the 158 
experiments described in Figure S6 ruled out this scenario. A second possibility is that 159 
the acquired spacer provides only partial immunity, i.e. a proportion of the adapted cells 160 
can be lysed by the phage and produce CRISPR-transducing particles. To test this, we 161 
measured immunity using an assay that reproduces the high MOI faced by cells that 162 
acquire new spacers33. In these conditions, CRISPR-Cas systems programmed with the 163 
L and I spacers enabled the complete recovery of the host, and cells containing H1 and 164 
H2 spacers showed only a partial recovery of the infected staphylococci (Fig. 3A). To 165 
determine the strength of the immunity mediated by all the spacers present in the 166 
CRISPR-transducing particles (not just H1 and H2), we followed the survival of naïve 167 
  
staphylococci upon infection with phages collected during the CRISPR-Cas immune 168 
response (Fig. 1D, 22 hour time-point), which contain both ΦNM4γ4 as well as 169 
transducing particles that can provide immunity against the phage. We obtained similar 170 
partial survival curves to those provided by the H1- and H2-containing CRISPR-Cas 171 
systems (Fig. 3B). These results suggest that the complete destruction of the virus by 172 
the intermediate- and low-transducing spacers limits the formation of CRISPR-173 
transducing particles. If true, these spacers should have a dominant effect on the H1 174 
and H2 spacers, i.e. they will reduce their frequency of transduction. To test this, we 175 
combined different pairs of pCRISPR plasmids (with different antibiotic-resistance 176 
markers) in the same cell, infected them with ΦNM4γ4 and counted the number of 177 
transductants (Fig. 3C). We found that the combination of CRISPR-Cas systems 178 
harboring I or L spacers with either H1 or H2 spacers resulted in a low transduction 179 
frequency, i.e. the effect of I and L spacer predominate over H1 and H2. Similarly, a 180 
reduction in the transduction of a second plasmid (pE194, 2.9 kb) is observed in cells 181 
containing I and L spacers when compared to H1 and H2 (Fig. S7A). Finally, we looked 182 
at the transduction of pCRISPR plasmids harboring an inactivating mutation in Cas9 183 
(dCas98). Corroborating our hypothesis, the reduction in immunity caused by this 184 
mutation enhanced the transduction rate for spacers I, H1, and H2 (Figs. S7BC). 185 
Altogether, these results demonstrate that spacer/phage recombination is the primary 186 
driver of spacer-enhanced transduction and that spacer sequences mediating highly 187 
efficient CRISPR immunity prevent the transduction of the CRISPR-cas locus. 188 
Here we show that spacers acquired by CRISPR-Cas systems can perform a form of 189 
specialized transduction that requires their recombination with the phage target as well 190 
as incomplete CRISPR immunity (Fig. 3D). The recombination between the spacer and 191 
  
its viral target connects the locus with the packaging sequences on the phage genome, 192 
enabling foreign DNA uptake at much higher rates than observed during typical 193 
generalized transduction in our experimental system. If the CRISPR locus resides in the 194 
host chromosome, this recombination can mediate the transfer of genes adjacent to the 195 
CRISPR locus and thus facilitate the dissemination and exchange of cas modules. If the 196 
CRISPR-Cas system resides in a circular genetic element, spacer-mediated 197 
recombination leads to the spread of CRISPR immunity among naïve CRISPR-negative 198 
hosts. Interestingly, the host RecA is not required for protospacer-spacer recombination, 199 
a result suggesting that this phenomenon is mediated by the phage’s own machinery, 200 
which can significantly elevate recombination rates34,35. Our analysis of four different 201 
spacers showed that transduction rates are higher for spacers that mediate poor 202 
cleavage of the pCRISPR/ΦNM4γ4 recombinants. We believe that the next-generation 203 
sequencing experiment shown in Fig. 2A, which includes data for all transduced 204 
spacers, supports this correlation: the sequences of the spacers mediating the lowest 205 
transduction rates (5 to 20 kb of the ΦNM4γ4 genome) are located around the pac site, 206 
which a previous study showed to be one of the regions of this phage best targeted by 207 
Cas936.  208 
Our data shows that both types of spacer-enhanced transduction events we describe 209 
here occur at very low frequencies. However, as it is the case with most situations 210 
involving horizontal transfer of genetic material, the importance of these events relies 211 
not so much in their rate of occurrence, but in their capacity to increase the genetic pool 212 
of the recipients37; given the appropriate environmental conditions, the genes and 213 
plasmids transferred though spacer-mediated transductions could provide a crucial 214 
selective advantage to the population. For example, the exchange of CRISPR-adjacent 215 
  
modules could expand the repertoire of cas genes of a CRISPR locus and generate the 216 
genetic diversity13-15 required to stay ahead in the arms race with different phages and 217 
their anti-CRISPR inhibitors38. Plasmids and potentially excisable genomic islands 218 
harboring CRISPR-Cas loci are relatively common31,39, and their spread though spacer-219 
mediated transduction could provide critical spacers and/or full defense cassettes for 220 
phage defense. Even if the transduced CRISPR-Cas locus does not harbor the most 221 
efficient spacers, as our data indicates, their spread can increase the spacer diversity 222 
necessary to prevent the raise of phage escapers40 and/or provide partial defense to 223 
enable the acquisition of more potent sequences. Finally, it is worth noting that 224 
CRISPR-Cas systems have been identified within phage genomes41-43. Although we do 225 
not know their origin, it is possible that these arose by the type of spacer-mediated 226 
recombination we demonstrated in this study. 227 
It is interesting to consider that acquired spacers could have a dual role during CRISPR 228 
immunity: a major one in the generation of crRNA guides and a minor one in mediating 229 
HGT. In support of this idea, recent work has found Tn7-like transposons that harbor 230 
orphan CRISPR arrays, not flanked by effector cas genes, in which dissemination is 231 
likely facilitated by spacers44. Circumstantial evidence that this second role may be 232 
important comes from the mechanism of crRNA biogenesis. In the S. pyogenes type II-233 
A CRISPR-Cas pathway, the 10 nucleotides at the 5’ end of the spacer sequence on 234 
the crRNA are degraded and eliminated from the Cas9 ribonucleoprotein complex, 235 
making this region of the spacer dispensable for targeting8. As recombination increases 236 
with the extent of homology, it is possible that this additional 10 nucleotides in the 237 
spacer DNA could facilitate transduction (Fig. S8). Type III-A spacers also have 3’ end 238 
sequences that eliminated from the spacer RNA sequence during CRISPR-RNA 239 
  
maturation45, and while not shortened, crRNA-target homology at the 3’ end of type I-E 240 
spacers is not necessary for targeting46. Therefore, it is tempting to speculate that the 241 
acquisition of spacers has evolved not only to incorporate foreign sequences for 242 
defense against predation, but also as a means of hijacking the mobilization machinery 243 
of these elements to spread through prokaryotic populations.  244 
  
Supplementary information 245 
Supplementary information Figures S1-S6. 246 
Supplementary information Tables S1-S2. 247 
Supplementary information Data File 1. 248 
 249 
Acknowledgements. We would like to thank Joshua W. Modell, Jakob T. Rostol, and 250 
Alissa M. Pham for helpful discussion and critical reading of the manuscript. JWM also 251 
provided strains pAV293-296. AV is supported by the Arnold O. Beckman Postdoctoral 252 
Fellowship. LAM is supported by the Rita Allen Scholars Program and an NIH Director’s 253 
Pioneer Award (DP1GM128184-01). The work carried out by ERW and SM was 254 
supported by the Biotechnology and Biological Sciences Research Council 255 
(BB/N017412/1) and Natural Environment Research Council (NE/M018350/1). 256 
 257 
Author Contributions. AV and LAM conceived the study. AV, SM, RB, ERW, and LAM 258 
designed experiments. AV executed the experimental work and SM executed the 259 
experimental work with P. aeruginosa. AV, SM, RB, ERW, and LAM wrote the paper. 260 
 261 
Author Information. The authors have no conflicting financial interests. 262 
Correspondence and requests for materials should be addressed to 263 
marraffini@rockefeller.edu.  264 
  
Methods 265 
Bacterial strains and growth conditions 266 
Culture of Staphylococcus aureus RN422047 was carried out in brain-heart infusion 267 
(BHI) medium at 37°C with agitation at 220 revolutions per minute. Liquid experiments 268 
were carried out in 3 milliliters of medium in 15 ml conical tubes unless otherwise noted. 269 
S. aureus media was supplemented with 10 μg/ml chloramphenicol, 10 μg/ml 270 
erythromycin, or 25 μg/ml kanamycin for plasmid maintenance and/or chromosomal 271 
marker selection.  272 
Culture of Streptococcus thermophilus was carried out in M17 media supplemented with 273 
10% lactose at 37°C without agitation, unless otherwise noted. Liquid experiments were 274 
carried out in 5 milliliters of media in 15 ml conical tubes. M17 media was supplemented 275 
with 5 μg /ml chloramphenicol, 200 μg/ml spectinomycin, or 2.5 μg/ml erythromycin for 276 
chromosomal marker selection. 277 
Culture of Pseudomonas aeruginosa was carried out in LB media at 37°C with agitation 278 
at 180 revolutions per minute. LB media was supplemented with 100 μg/ml streptomycin 279 
or 30 μg/ml gentamycin for chromosomal marker selection 280 
All strains are listed in Table S1.  281 
Quantification of CRISPR-Cas transducing particles 282 
In S. aureus, overnight cultures of pWJ4033 or pC19448 were diluted 1:100 in fresh BHI 283 
with appropriate antibiotics and 5 mM CaCl2. At OD600 = 0.4, cultures were infected with 284 
ΦNM4γ433 at a multiplicity of infection (MOI) 1. Phage was collected at indicated time 285 
points and filtered with 0.45-μm syringe filters (Acrodisc). Harvested phage were then 286 
used to infect lawns of S, aureus strain OS249 suspended in 50% BHI supplemented 287 
with 5 mM CaCl2 at an MOI of 1 on a BHI base supplemented with erythromycin and 288 
chloramphenicol to select for recipient cells and CRISPR-Cas transduction. For 289 
quantification of transducing particles produced from strains already containing 290 
CRISPR-immunity, overnight cultures were diluted 1:100 in fresh BHI with appropriate 291 
antibiotics and 5 mM CaCl2. At OD600 = 0.4, cultures were infected with ΦNM4γ4 or 292 
Φ12γ336 at a MOI of 50. 90 minutes post infection, phage were collected and filtered 293 
with 0.45-μm syringe filters (Acrodisc). Harvested phage were then used to infect lawns 294 
of OS2 suspended in 50% BHI supplemented with 5mM CaCl2 at an MOI of 1 on a BHI 295 
base supplemented with erythromycin and chloramphenicol to select for recipient cells 296 
and CRISPR-Cas transduction. Phages that were not of sufficient titers to infect at an 297 
MOI of 1 were supplemented with the appropriate phage prepared from RN4220. 298 
Detection of spacer acquisition 299 
To check for spacer acquisition in S. aureus, transduced colonies were resuspended in 300 
colony lysis buffer (250 mM KCl, 5 mM MgCl2 50 mM Tris-HCl at pH 9.0, 0.5% Triton X-301 
100), treated with 200 ng/µl lysostaphin and incubated at 37°C for 20 minutes, then 302 
98°C for 10 minutes. Samples were centrifuged and supernatant was used for PCR 303 
amplification with primers L400 and H50.  304 
  
CRISPR adaptation and escaper phage generation 305 
For P. aeruginosa, to monitor the effect of increased homology between the CRISPR 306 
system and the phage DMS3vir genome, we cultured PA14-Sm in the presence of 307 
DMS3vir and isolated a phage-resistant mutant that had acquired an additional spacer 308 
targeting the phage, following procedures previously described30. Next, we isolated 309 
DMS3vir ‘escape’ mutants by inoculating a 96 well plate with 200 μl of the CRISPR-310 
resistant PA14-Sm strain and ~6*107 DMS3vir. After a 24-hour incubation at 37°C 311 
phages were isolated by chloroform extraction and spotted onto a lawn of the CRISPR-312 
resistant PA14-Sm. Individual ‘escape’ phage clones were isolated, followed by 313 
sequencing of the amplicon containing the protospacer and PAM sequences. A single 314 
‘PAM-escape’ mutant was used in the transduction assays (G>A, position 25926) along 315 
with the WT DMS3vir phage.  316 
For S. thermophilus, we isolated bacterial colonies that had acquired spacers in the 317 
erythromycin-tagged CRISPR1 locus of JAV28 following infection by phage 2972 using 318 
procedures previously described50. Genomic DNA from strain JAV33 was amplified and 319 
sequenced with AV638-AV724 and found to have a spacer targeting the top strand 320 
beginning at position 26,553 of 2972. Phage 2972 was passaged on this strain for 321 
escapers on soft-agar. Single plaques were isolated and re-passaged to single plaques 322 
on JAV33. Phage DNA was extracted by boiling the phage and 2972α1 DNA was 323 
amplified and sequenced with AV868-AV869. 2972α1 contained a mutation in the PAM 324 
region (A>G, 26,588) 325 
Quantification of transduction 326 
For S. aureus, overnight donor cultures were diluted 1:100 in fresh BHI with appropriate 327 
antibiotics and 5 mM CaCl2. At OD600 = 0.4, cultures were infected with either ΦNM4γ4 328 
at a MOI of 1 or 85α1-3 and ΦNM1γ6 at an MOI of 50. Following lysis of the culture at 2 329 
hours, phages were collected and filtered with a 0.45-μm syringe filters (Acrodisc). 330 
Overnight recipient cultures were diluted 1:100 in fresh BHI with appropriate antibiotics 331 
and 5 mM CaCl2. At OD600 = 0.4, cultures were infected at an MOI of 1 with the 332 
transducing phage. 20 minutes post-infection, 40 mM of sodium citrate was added to 333 
the cultures. For erythromycin transduction, the cells were incubated for an additional 334 
40 minutes then pelleted and washed twice with fresh BHI supplemented with 40 mM 335 
sodium citrate, while for chloramphenicol transduction cells were washed immediately. 336 
Cells were then plated on BHI plates supplemented with the antibiotics selecting for the 337 
recipient strain and transduction marker along with 20 mM sodium citrate for type II-A 338 
plasmids and no sodium citrate for type III-A plasmids. 339 
For P. aeruginosa, bacterial lawns with near-confluent lysis were generated by mixing 340 
200 μl of PA14-Sm on overnight cultures with 20μl of ~104 PFU DMS3vir and 10 mL soft 341 
LB agar. Phage only controls were included by applying the same protocol, but 342 
excluding the addition of bacteria. After 24-hour incubation at 37°C, phages were 343 
harvested by soaking the lawns in 3 mL of M9 salts buffer for 1 hour at room 344 
temperature followed by chloroform extraction and titration of the resulting phage stock. 345 
As recipients, we used P. aeruginosa PA14 ΔCRISPR-Cas51 transformed with 346 
pHERD30T (conferring gentamycin resistance). 10 mL LB overnight culture 347 
supplemented with 30 μg mL-1 gentamycin of each recipient was spun down (3000 rpm, 348 
  
10 min) and re-suspended in 1 mL of LB. 100 μl of lysate was then added and statically 349 
incubated for 25 minutes. Each culture was then spun down and the whole culture was 350 
plated on LB agar supplemented with 100 μg mL-1 streptomycin and 30 μg mL-1 351 
gentamycin (to prevent carry over of PA14-Sm cells). To estimate transduction 352 
frequency, 48 colonies were picked per replicate experiment, and screened by PCR 353 
using primers specific for the CRISPR 2 locus primers CR2_F-CR2_R. 354 
For S. thermophilus, transducing phage stocks were made by infecting mid-log growth 355 
JAV33 at 42°C supplemented with 10 mM CaCl2 with either 2972 or 2972α1 at an MOI 356 
of 1. Phage stocks were harvested and filtered using 0.45-μm syringe filters (Acrodisc) 357 
after the culture had cleared. JAV27 were used as recipient cells and were grown to at 358 
42°C supplemented with 10 mM CaCl2 and infected at an MOI of 0.5 when cultures 359 
reached OD600 = 0.4. 10 minutes following infection, 20 mM sodium citrate was added to 360 
the cultures. After 1 hour incubation at 42°C, the cultures were washed two times in 361 
M17 media supplemented with 20 mM sodium citrate and then plated on erythromycin 362 
M17 plates. Transductants were confirmed by streaking out colonies on M17 363 
chloramphenicol plates to confirm antibiotic resistance engineered into the CRISPR3 364 
locus.  365 
Detection of phage-CRISPR junctions 366 
Overnight cultures were diluted 1:100 in fresh BHI with appropriate antibiotics and 5 mM 367 
CaCl2. At OD600 = 0.4, cultures were infected with ΦNM4γ4 at a MOI of 50 for targeting 368 
strains or 1 for non-targeting strains. Phages were collected from indicated strains 60 369 
minutes post-infection. Supernatants were filtered using a 0.45-μm filter and then 370 
concentrated with Ultra-4 100k centrifugal 50-ml spin columns (Amicon). Concentrates 371 
were resuspended with DNase I buffer, 20 mM Tris-HCl pH 8.0 and 2 mM MgCl2 and re-372 
concentrated two times. The suspension was then treated with 25 units of DNase I 373 
(Sigma) for one hour. Following DNAse I treatment, the enzyme was inactivated by 374 
heating at 70°C for 10 minutes and the addition of 5 mM EDTA. Phages were then 375 
incubated with 8 units of proteinase K (NEB) and 0.5% SDS at 37°C for one hour. 376 
Phage DNA was isolated using a phenol/chloroform/isoamyl alcohol extraction (Fisher). 377 
Cellular DNA was collected 15 minutes and 60 minutes post infection for non-targeting 378 
strains and targeting strains respectively. Approximately 109 cells were pelleted and 379 
resuspended in 100 μl of 50 mM EDTA and 1 mg/ml lysostaphin (AMBI Products) and 380 
incubated at 37°C for one hour. DNA was then extracted with the Wizard genomic 381 
purification kit (Promega) according to the manufacturer’s instructions. For the non-PAM 382 
junction, primer JM117 was used with NP255, AV547, AV469, AV471 for L, I, H1, and 383 
H2, respectively. For the PAM junction, primer L400 was used with AV457, AV458, 384 
AV456, AV459 for L, I, H1, and H2, respectively. For loading controls oGG38-oGG40 385 
were used to amplify gp14 and JW96-W964 for recA. 386 
High-throughput sequencing 387 
Overnight cultures of pWJ40 were diluted 1:100 in fresh BHI with appropriate antibiotics 388 
and 5 mM CaCl2.  At OD600 = 0.4, cultures were infected with ΦNM4γ4 at a MOI of 1. 20 389 
hours post-infection DNA was collected from recovered cells (CRISPR-resistant). 390 
Phages were also collected and filtered with 0.45-μm syringe filters (Acrodisc). 391 
Overnight cultures of OS2 were diluted 1:100 in fresh BHI with appropriate antibiotics 392 
  
and 5 mM CaCl2.  At OD600 = 0.4, cultures were infected with ΦNM4γ4 collected from 393 
the pWJ40 culture at a MOI of 1. 20 hours post-infection DNA was collected from 394 
recovered cells (CRISPR-transduced). Spacers were amplified with RH50 and JW655-395 
JW662 for sample barcoding. The sequences of the oligonucleotides used in this study 396 
are listed in Table S2. Adapted bands were gel-extracted and subjected to Illumina 397 
MiSeq sequencing. Data analysis was performed in Python. Spacer reads were 398 
extracted from the raw MiSeq FASTA files and aligned to the phage genome. Number 399 
of reads and PAM were designated for each spacer. Spacers were normalized as reads 400 
per million and plotted against the ΦNM4γ4 genome in 2000-base-pair bins.deep 401 
sequence phage-CRISPR DNA junctions, cultures containing spacer H1 were infected 402 
with ΦNM4γ4 at a MOI of 50 and phages were collected 90 minutes post infection.  403 
Phage DNA was isolated as described above. DNA was then prepped with the Illumina 404 
TruSeq Nano kit according to the manufacturer’s instructions. Prepped DNA was then 405 
subject to NextSeq sequencing. BWA-MEM (arXiv:1303.3997v1) was used to align 406 
sequenced DNA to the PAM junction, which contains 200 base pairs of the upstream 407 
CRISPR sequence (leader and direct repeat) and 205 base pairs of the downstream 408 
phage sequence (Spacer, PAM, and phage genome) or the repeat junction, which 409 
contains 205 base pairs of the upstream phage sequence (phage genome and spacer, 410 
and 200 base pair downstream CRISPR sequence (direct repeat and downstream 411 
plasmid sequence). A python script was then used to sort and bin reads spanned the 412 
full 75-nucleotide read length allowing for one mismatch.  413 
Phage titer assay 414 
Phage titer assays were performed as previously described52. 415 
Efficiency of plaquing assays 416 
Efficiency of plaquing assays were performed as previously described52. 417 
Simulation of CRISPR immunization 418 
Simulation of CRISPR immunization was performed as previously described53. 419 
Strain construction 420 
To make the recA knockout JAV9, the allelic replacement system developed by Wenyan 421 
Jiang using pWJ244 was applied as previously described36. Briefly, pAV44 was 422 
transformed into RN4220 and integrants were isolated. Double crossover events were 423 
selected for by a temperature sensitive cat targeting Cas9 phagemid, pWJ326. RecA 424 
deletion was confirmed by primers outside the homology arms, AV223 and AV224.  To 425 
make JAV21, OS2 was infected with ΦNM1γ652 at an MOI of 1 to produce transducing 426 
particles carrying the genomic erythromycin cassette. These particles were used to 427 
infect JW26336 as described in quantification of transduction. Colonies that were 428 
resistant to kanamycin and erythromycin were struck out 2 times on plates 429 
supplemented with 20mM sodium citrate, kanamycin, and erythromycin. JAV29 and 430 
JAV32 were constructed by transforming suicide vectors pAV253 and pAV282. 431 
Integration was confirmed using primers AV594 and AV812 for pAV253 and AV648 and 432 
AV525. JAV33 was made by infecting RN4220 at MOI of 1 in soft agar with ΦNM4γ4. 433 
  
After a 24-hour incubation, a resistant colony was picked, restreaked two times, and 434 
confirmed to be insensitive to ΦNM4γ4 infection.  435 
To create a P. aeruginosa PA14 strain carrying a streptomycin resistance cassette 436 
immediately adjacent to the Type I-F CRISPR-Cas system in the genome (PA14-Sm, 437 
with the Sm gene inserted at position 2937360), we used homologous recombination. 438 
The streptomycin (Sm) resistance gene and its promoter were PCR amplified from 439 
pBAM1-Sm54 using primers pB_Sm_F and pB_Sm_R, and inserted into the NheI 440 
restriction site of pHERD30T, flanked by amplicons FL1 (flank1, generated using primer 441 
pairs FL1_F and FL1_R) and FL2 (flank2, generated using primer pairs FL2_F and 442 
FL2_R). To select for recombinants, a crRNA targeting the junction between the 443 
flanking sequences was expressed from the same plasmid. 444 
To create S. thermophilus strains, PCR products were generated with homology arms 445 
approximately 2 kilobases long that flank antibiotic resistant cassettes and transformed 446 
into the wildtype strains. For JAV27, CRISPR1 was eliminated by amplifying homology 447 
arms with AV664-AV665 and AV666-AV667. The spectinomycin resistance cassette 448 
was amplified from pLZ12spec55 with AV672-AV673 and a three piece Gibson assembly 449 
was used to create the final product for transformation. Also in JAV27, CRISPR3 was 450 
eliminated by amplifying homology arms with AV668-AV669 and AV682-AV683. The 451 
chloramphenicol resistance cassette was amplified from pC19448 with W1055-W1056 452 
and a three piece Gibson assembly was used to create the final product for 453 
transformation. JAV27 was made by first knocking out CRISPR1 and then repeating the 454 
procedure for CRISPR3. For JAV28, CRISPR1 was tagged with erythromycin 455 
resistance by amplifying homology arms with AV667-AV692 and AV693-AV694. The 456 
erythromycin cassette was amplified from pE19456 with AV177-AV695 and a three piece 457 
Gibson assembly was used to create the final product for transformation. To transform 458 
assembled DNA fragments into cells, an overnight culture was washed once in 459 
chemically-defined medium (CDM)57, then diluted 1:100 in one milliter of CDM. 460 
Following 1.5 hours of incubation at 37°C, 10 µl of the Gibson product along with 1 µM 461 
ComS17-24 peptide58 (LPYFAGCL, Genescript) were added. Following a 4-hour 462 
incubation, cells were plated with the appropriate antibiotic and incubated for 36 hours.  463 
Phage construction 464 
To create phages to study transduction in S. aureus 08BA0217628, phage 8529 was 465 
used to infect this strain at a high MOI on soft-agar. 85α1 was isolated for its ability to 466 
form plaques on 08BA02176. To make 85α2, the 08BA02176 type III-A target was 467 
inserted site early-genome. 85α1 was passaged on soft-agar on a strain containing 468 
pAV247, a plasmid containing ~1 kilobase phage-homology arms where a small, 469 
unessential portion of the phage genome was replaced with the type III-A spacer 1 470 
target. This phage stock was then passaged on soft-agar on a strain containing 471 
pGG1252, a plasmid containing a CRISPR-Cas system that targets the portion of the 472 
phage replaced with the 08BA02176 spacer 1 target. Plaques were picked from this 473 
passage and re-passaged to single plaques on soft-agar a second time. Phages were 474 
then amplified and sequenced with oGG38-oGG40 to confirm target insertion. To make 475 
85α3, the 08BA02176 type III-A target was inserted site mid-genome. 85α1 was 476 
passaged on soft-agar on a strain containing pAV282, a plasmid containing ~1 kilobase 477 
  
phage-homology arms with an insertion into the phage genome with the type III-A 478 
spacer 1 target. This phage stock was then passaged on soft-agar on a strain 479 
containing pAV284, a plasmid containing a CRISPR-Cas system that targets the portion 480 
of the phage interrupted with the 08BA02176 spacer 1 target. Plaques were picked from 481 
this passage and re-passaged to single plaques on soft-agar a second time. Phages 482 
were then amplified and sequenced with AV876-AV877 to confirm target insertion. 483 
Plasmid construction 484 
All plasmids were constructed using electro-competent cells as described elsewhere52. 485 
The sequences of the oligonucleotides used in this study are listed in Table S2. To 486 
create recA allelic exchange vector pAV44, a three-piece Gibson assembly was 487 
performed using W1005-W1055 to amplify pWJ24436,with  AV206-AV208 and AV207-488 
AV209 to amplify the homology arms from RN4220. AV149, pAV150, pAV153, pAV155, 489 
high- and low-transducing spacers targeting ΦNM4γ4, were assembled by using BsaI 490 
cloning described in detail elsewhere59. Primer pairs AV404-AV405, AV406-AV407, 491 
AV412-AV413, and AV416-AV417 were annealed and ligated into pDB11459, to 492 
construct the respective plasmids. To make Φ12γ336 targeting plasmids, pAV293, 493 
pAV294, pAV295, and pAV296, BsaI cloning was used to insert JW600-JW601, JW604-494 
JW605, JW620-JW621, and JW695-JW696 into pDB114 respectively. To make 495 
pAV158, pAV159, pAV162, pAV164, and pAV165, one piece Gibson assembly was 496 
performed using H235-H236 to remove cas9 from pAV149, pAV150, pAV153, pAV155, 497 
and pDB114, respectively. To transfer high and low-transducing spacers to a pE19456 498 
background, a two-piece Gibson assembly was used. AV176 and AV177 were used to 499 
amplify pE194 and AV423-AV424 were used to amplify the tracrRNA, cas9, and 500 
CRISPR array cassette. pAV149, pAV150, pAV153, and pAV155 were used as 501 
templates for pAV175, pAV173, pAV174, and pAV176, respectively. To make pAV185, 502 
the last 10-basepairs of H1 were complemented. BsaI cloning was used to insert 503 
annealed oligonucleotides AV485-AV486 into pDB114. pAV195 was made with a one-504 
piece Gibson assembly, where pAV185 was amplified with H235-H236 to remove cas9. 505 
To create phage 8529 editing plasmid pAV247 a three-piece Gibson was performed 506 
where pC19448 was amplified with AV186-AV204, and phage homology arms were 507 
amplified AV607-AV611 and AV609-AV610. To create the construct to tag the type III-A 508 
locus with erythromycin a two-piece Gibson assembly was performed, where pTM40260 509 
was amplified with AV590-AV591 and the homology arm was amplified with AV622-510 
AV623 from 08BA02176 and grown in strain TM1760. To create phage 85 editing 511 
plasmid pAV281 a three-piece Gibson was performed where pC194 was amplified with 512 
AV186-AV204, and phage homology arms were amplified AV862-AV864 and AV863-513 
AV865. To add a spacer that targets phage 85 (5’- 514 
TTTCAACATTCTTCAACATACGCTGTCCTTGTGAGT-3’) to 08BA02176, pAV282 was 515 
made with a 3-piece Gibson assembly, where pTM402 was amplified with AV590-516 
AV591, and homology arms were amplified with AV879-AV880 and AV878-AV881. 517 
pAV282 was grown in TM17. To make phage 85 portal-targeting plasmid pAV284, BsaI 518 
cloning was used to insert AV866-AV867 into pDB114. To make dcas9 contstructs 519 
pAV305, pAV306, pAV307, pAV308, and pAV309 gibson assembly was performed 520 
where B338-B339 were used to amplify cas9 from pDB114 and B337-B340 were used 521 
to amplify the plasmid backbone and spacer from pAV149, pAV150, pAV153, pAV155, 522 
and pDB114, respectively.  523 
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Figures 703 
 704 
Fig. 1. Transfer of CRISPR elements through phage transduction. (A) Following 705 
phage recombination with a chromosomal CRISPR-Cas locus, adjacent loci can be 706 
preferentially transduced. “R” represents CRISPR repeats, “S” CRISPR spacers, brown 707 
the phage genome (B) Transducing particle production from S. aureus strain 708 
08BA02176 tagged with an erythromycin resistance cassette. Liquid cultures were 709 
infected with 85α1 at a MOI (multiplicity of infection) of 50 for the control (ctl) or 710 
targeting strains (P1, P2, C1) and phages were collected 90 minutes post infection. 711 
Wild-type 08BA02176 was infected with transducing phages and a MOI of 1 for 20 712 
minutes, then treating with sodium citrate. After 40 minutes cells were washed and 713 
plated on erythromycin-containing solid media. Mean + STD of 3 biological replicates 714 
are reported. (C) Phage recombination with a plasmid-borne CRISPR-Cas locus on 715 
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circular element. Following recombination between the spacer and the phage genome, 716 
the phage packaging machinery preferentially packages the phage-linked locus. Upon 717 
injection into the recipient cell the element re-circularizes. “R” represents CRISPR 718 
repeats, “S” CRISPR spacers, brown the phage genome. (D) Cell growth and titers of 719 
infected cultures containing plasmids with either the type II-A CRISPR system from S. 720 
pyogenes (CRISPR+) or the empty vector control (CRISPR-). Liquid cultures were 721 
infected at a multiplicity of infection (MOI) of 1 with ΦNM4γ4. The growth of cultures 722 
was determined by measurement of optical density at 600 nm (OD600). Titers, plaque 723 
forming units/ml (pfu/ml), were determined by filtering supernatant and plaquing. Levels 724 
of transducing-immune phage particles, colony forming units/ml (cfu/ml), were 725 
determined by infecting a susceptible culture at a MOI of 1 and plating on soft agar 726 
lawns with antibiotic selection for recipient cells and the CRISPR plasmid. No 727 
transducing-immune particles were detected using a vector control. Time points were 728 
taken from 0-24 hours, every 2 hours. Mean ± STD of 3 biological replicates are 729 
reported. (E) Levels of transduction during adaption were determined by mixing cells at 730 
a 1:5 naïve CRISPR to CRISPR- cell ratio and infected at an MOI of 1 with ΦNM4γ4. 731 
Cultures were collected 20 hours post infection and assayed for the presence of the 732 
CRISPR-Cas locus by plating for the antibiotic resistance of the CRISPR plasmid. 733 
Levels of transduction were determined by plating for the antibiotic resistance encoded 734 
by the CRISPR-Cas plasmid and the chromosomal antibiotic resistance markers of the 735 
CRISPR- cells. As a control, cells resistant to phage infection independent of CRISPR, 736 
where mixed with naïve CRISPR cell under the conditions described above. Mean ± 737 
STD of 3 biological replicates are reported.  738 
  
 739 
Fig. 2. Spacers sequences determine frequency of CRISPR-Cas transduction. (A) 740 
Cultures containing the type II-A pCRISPR were infected with ΦNM4γ4 at a MOI of 1. 741 
DNA was extracted 20 hours post infection and used as template for the amplification of 742 
expanded CRISPR arrays. The PCR products were analyzed by next-generation 743 
sequencing. Adapted spacers were normalized as reads per million and plotted against 744 
the ΦNM4γ4 genome in 2000-base-pair bins (blue line, CRISPR-resistant). Phages 745 
collected at 20 hours post infection were used to infect a culture lacking CRISPR-Cas 746 
loci at an MOI of 1. Recovered cultures were collected at 20 hours post infection and 747 
  
DNA was extracted. As described above, DNA was extracted for PCR and next-748 
generation sequencing and plotted against the phage genome (green line, CRISPR-749 
transduced). The ratio of transduced spacers over resistant spacers was also plotted 750 
(black line). Positions of low- (L), intermediate- (I), and highly-transduced spacers (H1, 751 
H2) used in subsequent experiments, along with phage pac site are indicated on graph. 752 
Mean of 4 replicates are reported. (B) Transducing-immune particles produced by cells 753 
expressing Cas9 and control (ctl), or targeting spacers (L, I H1, H2). Cultures were 754 
infected with ΦNM4γ4 at a MOI of 50 and phages were collected 90 minutes post 755 
infection. Levels of transducing-immune phage particles were determined by infecting a 756 
susceptible culture at a MOI of 1 and plating on soft agar lawns with antibiotic selection 757 
for recipient cells and the antibiotic resistance cassette on the pCRISPR plasmid. Mean 758 
+ STD of 3 biological replicates are reported. (C) Transduction of plasmids containing 759 
only the CRISPR array with either a control spacer (ctl) or ΦNM4γ4-targeting (L, I, H1, 760 
H2) spacers (pSpacer). Cultures were infected with ΦNM4γ4 at a MOI of 1 and phage 761 
was collected 2 hours post infection. Levels of transduction were determined by 762 
infecting a susceptible culture at a MOI of 1 for 20 minutes, washing cells, and plating 763 
for the antibiotic resistance of the plasmid. Mean + STD of 3 biological replicates are 764 
reported. (D) PCR analysis of products produced from phage/CRISPR-Cas locus 765 
recombinants. Cells containing just the CRISPR array (-Cas9) or Cas9 and the CRISPR 766 
array (+Cas9) or were infected at a MOI of 1 and 50, respectively. 30 minutes post 767 
infection for –Cas9 strains or 60 minutes post infection for +Cas9 strains, genomic DNA 768 
was extracted from the cellular pellet (cell DNA). For all strains, 60 minutes post 769 
infection DNA was also extracted from filtered supernatant (phage DNA). Primers 770 
annealing to the CRISPR-Cas locus and the corresponding portion of the phage 771 
genome were used to amplify recombination products at the indicated junction (Figure 772 
1C). (E) Deep sequencing of phage DNA harvested after infection of cells containing 773 
Cas9 and spacer H1. Cultures were infected with ΦNM4γ4 at a MOI of 50 and phages 774 
were collected 90 minutes post infection. Phage DNA was subject to deep sequencing 775 
and aligned to 300 base pairs of the phage CRISPR locus junction that does not contain 776 
the PAM. Each point on the graph represents the number of reads that originate at that 777 
nucleotide position and have full coverage to the right for the 75-nucleotide deep 778 
sequencing read. Dotted lines indicate portion of reads that map to the CRISPR locus 779 
and ΦNM4γ4. (F) Transduction of plasmids containing just the CRISPR array with either 780 
a control spacer (ctl) or ΦNM4γ4-targeting (L, H1) spacers (pSpacer) in a wildtype or 781 
RecA null (recA-) background. Cultures were infected with ΦNM4γ4 at a MOI of 1 and 782 
phage was collected 2 hours post infection. Levels of transduction were determined by 783 
infecting a susceptible culture at a MOI of 1 for 20 minutes, washing cells, and plating 784 
for the antibiotic resistance of the plasmid. Mean + STD of 3 biological replicates are 785 
reported. (G) Transducing-immune particles produced by cells expressing Cas9 and 786 
control spacers (ctl), or targeting- spacers (P51-like, duTPAse, HNH, hHydrolase H1, 787 
H2). Cultures were infected with Φ12γ3 at a MOI of 50 and phages were collected 90 788 
minutes post infection. Levels of transducing-immune phage particles were determined 789 
by infecting a susceptible culture at a MOI of 1 and plating on soft agar lawns with 790 
antibiotic selection for recipient cells and the antibiotic resistance cassette on the 791 
CRISPR plasmid. Mean + STD of 3 biological replicates are reported. Limit of detection 792 
is 3.3 cfu/ml (dotted line).  793 
  
 794 
Fig. 3. Efficiency of CRISPR immunity inversely correlates with transduction 795 
rates. (A) Simulation of CRISPR adaptation in cells expressing spacers with high-, 796 
intermediate-, and low-transducing phenotypes (L, I, H1, H2) or a control spacer (ctl). 797 
Cells lacking CRISPR were used to dilute immune culture 1:10,000 and then infected at 798 
a final MOI of 1. These were compared to an uninfected control (no phage). Cell growth 799 
was monitored by optical density measurements at 600 nm (OD600). Mean - STD of 3 800 
biological replicates are reported. (B) Cells lacking CRISPR were infected at an MOI of 801 
1 with phage collected from a culture containing an adapting CRISPR plasmid or a 802 
vector control at 22 hours post infection. Cell growth was monitored by optical density 803 
measurements at 600 nm (OD600). Mean - STD of 5 biological replicates are reported. 804 
(C) Transducing particle production from spacers combined with a second plasmid 805 
containing the spacer indicated in figure legend/bar color. The transduction efficiency of 806 
the spacer on the x-axis was assayed for CRISPR function and antibiotic resistance. 807 
Cultures were infected with ΦNM4γ4 at a MOI of 50 and phages were collected 90 808 
minutes post infection. Levels of transducing-immune phage particles were determined 809 
by infecting a susceptible culture at a MOI of 1 and plating on soft agar lawns with 810 
antibiotic selection for recipient cells and the antibiotic resistance cassette on the 811 
CRISPR plasmid. Limit of detection is 1.5 cfu/ml (dotted line). Mean + STD of 3 812 
biological replicates are reported. (D) Spacers acquired during CRISPR adaptation can 813 
be divided in to 2 classes, spacers that provide full immunity with low levels of 814 
transduction or spacers that provide partial immunity but facilitate transduction. The 815 
acquisition of spacers provides sufficient homology to target recombination of the phage 816 
genome with the CRISPR-Cas locus. Spacers that provide partial immunity allow for 817 
occasional lysis and targeted packaging of recombination substrates. 818 
819 
  
Methods 820 
Bacterial strains and growth conditions 821 
Culture of Staphylococcus aureus RN422050 was carried out in brain-heart infusion 822 
(BHI) medium at 37°C with agitation at 220 revolutions per minute. Liquid experiments 823 
were carried out in 3 milliliters of medium in 15 ml conical tubes unless otherwise noted. 824 
S. aureus media was supplemented with 10 μg/ml chloramphenicol, 10 μg/ml 825 
erythromycin, or 25 μg/ml kanamycin for plasmid maintenance and/or chromosomal 826 
marker selection.  827 
Culture of Streptococcus thermophilus was carried out in M17 media supplemented with 828 
10% lactose at 37°C without agitation, unless otherwise noted. Liquid experiments were 829 
carried out in 5 milliliters of media in 15 ml conical tubes. M17 media was supplemented 830 
with 5 μg /ml chloramphenicol, 200 μg/ml spectinomycin, or 2.5 μg/ml erythromycin for 831 
chromosomal marker selection. 832 
Culture of Pseudomonas aeruginosa was carried out in LB media at 37°C with agitation 833 
at 180 revolutions per minute. LB media was supplemented with 100 μg/ml streptomycin 834 
or 30 μg/ml gentamycin for chromosomal marker selection 835 
All strains are listed in Table S1.  836 
Quantification of CRISPR-Cas transducing particles 837 
In S. aureus, overnight cultures of pWJ4032 or pC19451 were diluted 1:100 in fresh BHI 838 
with appropriate antibiotics and 5 mM CaCl2. At OD600 = 0.4, cultures were infected with 839 
ΦNM4γ432 at a multiplicity of infection (MOI) 1. Phage was collected at indicated time 840 
points and filtered with 0.45-μm syringe filters (Acrodisc). Harvested phage were then 841 
used to infect lawns of S, aureus strain OS252 suspended in 50% BHI supplemented 842 
with 5 mM CaCl2 at an MOI of 1 on a BHI base supplemented with erythromycin and 843 
chloramphenicol to select for recipient cells and CRISPR transduction. For 844 
quantification of transducing particles produced from strains already containing 845 
CRISPR-immunity, overnight cultures were diluted 1:100 in fresh BHI with appropriate 846 
antibiotics and 5 mM CaCl2. At OD600 = 0.4, cultures were infected with ΦNM4γ4 or 847 
Φ12γ334 at a MOI of 50. 90 minutes post infection, phage were collected and filtered 848 
with 0.45-μm syringe filters (Acrodisc). Harvested phage were then used to infect lawns 849 
of OS2 suspended in 50% BHI supplemented with 5mM CaCl2 at an MOI of 1 on a BHI 850 
base supplemented with erythromycin and chloramphenicol to select for recipient cells 851 
and CRISPR transduction. Phages that were not of sufficient titers to infect at an MOI of 852 
1 were supplemented with ΦNM4γ4 prepared from RN4220. 853 
Detection of spacer acquisition 854 
To check for spacer acquisition in S. aureus, transduced colonies were resuspended in 855 
colony lysis buffer (250 mM KCl, 5 mM MgCl2 50 mM Tris-HCl at pH 9.0, 0.5% Triton X-856 
100), treated with 200 ng/µl lysostaphin and incubated at 37°C for 20 minutes, then 857 
98°C for 10 minutes. Samples were centrifuged and supernatant was used for PCR 858 
amplification with primers L400 and H50.  859 
  
CRISPR adaptation and escaper phage generation 860 
For P. aeruginosa, to monitor the effect of increased homology between the CRISPR 861 
system and the phage DMS3vir genome, we cultured PA14-Sm in the presence of 862 
DMS3vir and isolated a phage-resistant mutant that had acquired an additional spacer 863 
targeting the phage, following procedures previously described28. Next, we isolated 864 
DMS3vir ‘escape’ mutants by inoculating a 96 well plate with 200 μl of the CRISPR-865 
resistant PA14-Sm strain and ~6*107 DMS3vir. After a 24-hour incubation at 37°C 866 
phages were isolated by chloroform extraction and spotted onto a lawn of the CRISPR-867 
resistant PA14-Sm. Individual ‘escape’ phage clones were isolated, followed by 868 
sequencing of the amplicon containing the protospacer and PAM sequences. A single 869 
‘PAM-escape’ mutant was used in the transduction assays (G>A, position 25926) along 870 
with the WT DMS3vir phage.  871 
For S. thermophilus, we isolated bacterial colonies that had acquired spacers in the 872 
erythromycin-tagged CRISPR1 locus of JAV28 following infection by phage 2972 using 873 
procedures previously described53. Genomic DNA from strain JAV33 was amplified and 874 
sequenced with AV638-AV724 and found to have a spacer targeting the top strand 875 
beginning at position 26,553 of 2972. Phage 2972 was passaged on this strain for 876 
escapers on soft-agar. Single plaques were isolated and re-passaged to single plaques 877 
on JAV33. Phage DNA was extracted by boiling the phage and 2972α1 DNA was 878 
amplified and sequenced with AV868-AV869. 2972α1 contained a mutation in the PAM 879 
region (A>G, 26,588) 880 
Quantification of transduction 881 
For S. aureus, overnight donor cultures were diluted 1:100 in fresh BHI with appropriate 882 
antibiotics and 5 mM CaCl2. At OD600 = 0.4, cultures were infected with either ΦNM4γ4 883 
at a MOI of 1 or 85α1-3 at an MOI of 50. Following lysis of the culture at 2 hours, 884 
phages were collected and filtered with a 0.45-μm syringe filters (Acrodisc). Overnight 885 
recipient cultures were diluted 1:100 in fresh BHI with appropriate antibiotics and 5 mM 886 
CaCl2. At OD600 = 0.4, cultures were infected at an MOI of 1 with the transducing phage. 887 
20 minutes post-infection, 40 mM of sodium citrate was added to the cultures. For 888 
erythromycin transduction, the cells were incubated for an additional 40 minutes then 889 
pelleted and washed twice with fresh BHI supplemented with 40 mM sodium citrate, 890 
while for chloramphenicol transduction cells were washed immediately. Cells were then 891 
plated on BHI plates supplemented with the antibiotics selecting for the recipient strain 892 
and transduction events and 20 mM sodium citrate. 893 
For P. aeruginosa, bacterial lawns with near-confluent lysis were generated by mixing 894 
200 μl of PA14-Sm on overnight cultures with 20μl of ~104 PFU DMS3vir and 10 mL soft 895 
LB agar. Phage only controls were included by applying the same protocol, but 896 
excluding the addition of bacteria. After 24-hour incubation at 37°C, phages were 897 
harvested by soaking the lawns in 3 mL of M9 salts buffer for 1 hour at room 898 
temperature followed by chloroform extraction and titration of the resulting phage stock. 899 
As recipients, we used P. aeruginosa PA14 ΔCRISPR-Cas54 transformed with 900 
pHERD30T (conferring gentamycin resistance). 10 mL LB overnight culture 901 
supplemented with 30 μg mL-1 gentamycin of each recipient was spun down (3000 rpm, 902 
10 min) and re-suspended in 1 mL of LB. 100 μl of lysate was then added and statically 903 
  
incubated for 25 minutes. Each culture was then spun down and the whole culture was 904 
plated on LB agar supplemented with 100 μg mL-1 streptomycin and 30 μg mL-1 905 
gentamycin (to prevent carry over of PA14-Sm cells). To estimate transduction 906 
frequency, 48 colonies were picked per replicate experiment, and screened by PCR 907 
using primers specific for the CRISPR 2 locus primers CR2_F-CR2_R. 908 
For S. thermophilus, transducing phage stocks were made by infecting mid-log growth 909 
JAV33 at 42°C supplemented with 10 mM CaCl2 with either 2972 or 2972α1 at an MOI 910 
of 1. Phage stocks were harvested and filtered using 0.45-μm syringe filters (Acrodisc) 911 
after the culture had cleared. JAV27 were used as recipient cells and were grown to at 912 
42°C supplemented with 10 mM CaCl2 and infected at an MOI of 0.5 when cultures 913 
reached OD600 = 0.4. 10 minutes following infection, 20 mM sodium citrate was added to 914 
the cultures. After 1 hour incubation at 42°C, the cultures were washed two times in 915 
M17 media supplemented with 20 mM sodium citrate and then plated on erythromycin 916 
M17 plates. Transductants were confirmed by streaking out colonies on M17 917 
chloramphenicol plates to confirm antibiotic resistance engineered into the CRISPR3 918 
locus.  919 
Detection of phage-CRISPR junctions 920 
Overnight cultures were diluted 1:100 in fresh BHI with appropriate antibiotics and 5 mM 921 
CaCl2. At OD600 = 0.4, cultures were infected with ΦNM4γ4 at a MOI of 50 for targeting 922 
strains or 1 for non-targeting strains. Phages were collected from indicated strains 60 923 
minutes post-infection. Supernatants were filtered using a 0.45-μm filter and then 924 
concentrated with Ultra-4 100k centrifugal 50-ml spin columns (Amicon). Concentrates 925 
were resuspended with DNase I buffer, 20 mM Tris-HCl pH 8.0 and 2 mM MgCl2 and 926 
reconcentrated two times. The suspension was then treated with 25 units of DNase I 927 
(Sigma) for one hour. Following DNAse I treatment, the enzyme was inactivated by 928 
heating at 70°C for 10 minutes and the addition of 5 mM EDTA. Phages were then 929 
incubated with 8 units of proteinase K (NEB) and 0.5% SDS at 37°C for one hour. 930 
Phage DNA was isolated using a phenol/chloroform/isoamyl alcohol extraction (Fisher). 931 
Cellular DNA was collected 15 minutes and 60 minutes post infection for non-targeting 932 
strains and targeting strains respectively. Approximately 109 cells were pelleted and 933 
resuspended in 100 μl of 50 mM EDTA and 1 mg/ml lysostaphin (AMBI Products) and 934 
incubated at 37°C for one hour. DNA was then extracted with the Wizard genomic 935 
purification kit (Promega) according to the manufacturer’s instructions. For the non-PAM 936 
junction, primer JM117 was used with NP255, AV547, AV469, AV471 for L, I, H1, and 937 
H2, respectively. For the PAM junction, primer L400 was used with AV457, AV458, 938 
AV456, AV459 for L, I, H1, and H2, respectively. For loading controls oGG38-oGG40 939 
were used to amplify gp14 and JW96-W964 for recA. 940 
High-throughput sequencing 941 
Overnight cultures of pWJ40 were diluted 1:100 in fresh BHI with appropriate antibiotics 942 
and 5 mM CaCl2.  At OD600 = 0.4, cultures were infected with ΦNM4γ4 at a MOI of 1. 20 943 
hours post-infection DNA was collected from recovered cells (CRISPR-resistant). 944 
Phages were also collected and filtered with 0.45-μm syringe filters (Acrodisc). 945 
Overnight cultures of OS2 were diluted 1:100 in fresh BHI with appropriate antibiotics 946 
and 5 mM CaCl2.  At OD600 = 0.4, cultures were infected with ΦNM4γ4 collected from 947 
  
the pWJ40 culture at a MOI of 1. 20 hours post-infection DNA was collected from 948 
recovered cells (CRISPR-transduced). Spacers were amplified with RH50 and JW655-949 
JW662 for sample barcoding. The sequences of the oligonucleotides used in this study 950 
are listed in Table S2. Adapted bands were gel-extracted and subjected to Illumina 951 
MiSeq sequencing. Data analysis was performed in Python. Spacer reads were 952 
extracted from the raw MiSeq FASTA files and aligned to the phage genome. Number 953 
of reads and PAM were designated for each spacer.  954 
To deep sequence phage-CRISPR DNA junctions, phage DNA was isolated as 955 
described above. DNA was then prepped with the Illumina TruSeq Nano kit according to 956 
the manufacturer’s instructions. Prepped DNA was then subject to NextSeq sequencing. 957 
BWA-MEM (arXiv:1303.3997v1) was used to align sequenced DNA to the PAM 958 
junction, which contains 200 base pairs of the upstream CRISPR sequence (leader and 959 
direct repeat) and 205 base pairs of the downstream phage sequence (Spacer, PAM, 960 
and phage genome) or the repeat junction, which contains 205 base pairs of the 961 
upstream phage sequence (phage genome and spacer, and 200 base pair downstream 962 
CRISPR sequence (direct repeat and downstream plasmid sequence). A python script 963 
was then used to sort and bin reads spanned the full 75-nucleotide read length allowing 964 
for one mismatch.  965 
Phage titer assay 966 
Phage titer assays were performed as previously described55. 967 
Efficiency of plaquing assays 968 
Efficiency of plaquing assays were performed as previously described55. 969 
Simulation of CRISPR immunization 970 
Simulation of CRISPR immunization was performed as previously described35. 971 
Strain construction 972 
To make the recA knockout JAV9, the allelic replacement system developed by Wenyan 973 
Jiang using pWJ244 was applied as previously described34. Briefly, pAV44 was 974 
transformed into RN4220 and integrants were isolated. Double crossover events were 975 
selected for by a temperature sensitive cat targeting Cas9 phagemid, pWJ326. RecA 976 
deletion was confirmed by primers outside the homology arms, AV223 and AV224.  To 977 
make JAV21, OS2 was infected with ΦNM1γ655 at an MOI of 1 to produce transducing 978 
particles carrying the genomic erythromycin cassette. These particles were used to 979 
infect JW26334 as described in quantification of transduction. Colonies that were 980 
resistant to kanamycin and erythromycin were struck out 2 times on plates 981 
supplemented with 20mM sodium citrate, kanamycin, and erythromycin. JAV29 and 982 
JAV32 were constructed by transforming suicide vectors pAV253 and pAV282. 983 
Integration was confirmed using primers AV594 and AV812 for pAV253 and AV648 and 984 
AV525. JAV33 was made by infecting RN4220 at MOI of 1 in soft agar with ΦNM4γ4. 985 
After a 24 hour incubation, a resistant colony was picked, restreaked two times, and 986 
confirmed to be insensitive to ΦNM4γ4 infection.  987 
  
To create a P. aeruginosa PA14 strain carrying a streptomycin resistance cassette 988 
immediately adjacent to the Type I-F CRISPR-Cas system in the genome (PA14-Sm, 989 
with the Sm gene inserted at position 2937360), we used homologous recombination. 990 
The streptomycin (Sm) resistance gene and its promoter were PCR amplified from 991 
pBAM1-Sm56 using primers pB_Sm_F and pB_Sm_R, and inserted into the NheI 992 
restriction site of pHERD30T, flanked by amplicons FL1 (flank1, generated using primer 993 
pairs FL1_F and FL1_R) and FL2 (flank2, generated using primer pairs FL2_F and 994 
FL2_R). To select for recombinants, a crRNA targeting the junction between the 995 
flanking sequences was expressed from the same plasmid. 996 
To create S. thermophilus strains, PCR products were generated with homology arms 997 
approximately 2 kilobases long that flank antibiotic resistant cassettes and transformed 998 
into the wildtype strains. For JAV27, CRISPR1 was eliminated by amplifying homology 999 
arms with AV664-AV665 and AV666-AV667. The spectinomycin resistance cassette 1000 
was amplified from pLZ12spec57 with AV672-AV673 and a three piece Gibson assembly 1001 
was used to create the final product for transformation. Also in JAV27, CRISPR3 was 1002 
eliminated by amplifying homology arms with AV668-AV669 and AV682-AV683. The 1003 
chloramphenicol resistance cassette was amplified from pC19451 with W1055-W1056 1004 
and a three piece Gibson assembly was used to create the final product for 1005 
transformation. JAV27 was made by first knocking out CRISPR1 and then repeating the 1006 
procedure for CRISPR3. For JAV28, CRISPR1 was tagged with erythromycin 1007 
resistance by amplifying homology arms with AV667-AV692 and AV693-AV694. The 1008 
erythromycin cassette was amplified from pE19458 with AV177-AV695 and a three piece 1009 
Gibson assembly was used to create the final product for transformation. To transform 1010 
assembled DNA fragments into cells, an overnight culture was washed once in 1011 
chemically-defined medium (CDM)59, then diluted 1:100 in one milliter of CDM. 1012 
Following 1.5 hours of incubation at 37°C, 10 µl of the Gibson product along with 1 µM 1013 
ComS17-24 peptide60 (LPYFAGCL, Genescript) were added. Following a 4 hour 1014 
incubation, cells were plated with the appropriate antibiotic and incubated for 36 hours.  1015 
Phage construction 1016 
To create phages to study transduction in CRISPR type III-A containing strain 1017 
08BA0217629, phage 8530 was used to infect this strain at a high MOI on soft-agar. 85α1 1018 
was isolated for its ability to form plaques on 08BA02176. To make 85α2, the 1019 
08BA02176 type III-A target was inserted site early-genome. 85α1 was passaged on 1020 
soft-agar on a strain containing pAV247, a plasmid containing ~1 kilobase phage-1021 
homology arms where a small, unessential portion of the phage genome was replaced 1022 
with the type III-A spacer 1 target. This phage stock was then passaged on soft-agar on 1023 
a strain containing pGG1255, a plasmid containing a CRISPR system that targets the 1024 
portion of the phage replaced with the 08BA02176 spacer 1 target. Plaques were picked 1025 
from this passage and re-passaged to single plaques on soft-agar a second time. 1026 
Phages were then amplified and sequenced with oGG38-oGG40 to confirm target 1027 
insertion. To make 85α3, the 08BA02176 type III-A target was inserted site mid-1028 
genome. 85α1 was passaged on soft-agar on a strain containing pAV282, a plasmid 1029 
containing ~1 kilobase phage-homology arms with an insertion into the phage genome 1030 
with the type III-A spacer 1 target. This phage stock was then passaged on soft-agar on 1031 
a strain containing pAV284, a plasmid containing a CRISPR system that targets the 1032 
  
portion of the phage interrupted with the 08BA02176 spacer 1 target. Plaques were 1033 
picked from this passage and re-passaged to single plaques on soft-agar a second 1034 
time. Phages were then amplified and sequenced with AV876-AV877 to confirm target 1035 
insertion. 1036 
Plasmid construction 1037 
All plasmids were constructed using electro-competent cells as described elsewhere55. 1038 
The sequences of the oligonucleotides used in this study are listed in Table S2. To 1039 
create recA allelic exchange vector pAV44, a three-piece Gibson assembly was 1040 
performed using W1005-W1055 to amplify pWJ24434,with  AV206-AV208 and AV207-1041 
AV209 to amplify the homology arms from RN4220. AV149, pAV150, pAV153, pAV155, 1042 
high- and low-transducing spacers targeting ΦNM4γ4, were assembled by using BsaI 1043 
cloning described in detail elsewhere61. Primer pairs AV404-AV405, AV406-AV407, 1044 
AV412-AV413, and AV416-AV417 were annealed and ligated into pDB11461, to 1045 
construct the respective plasmids. To make Φ12γ334 targeting plasmids, pAV293, 1046 
pAV294, pAV295, and pAV296, BsaI cloning was used to insert JW600-JW601, JW604-1047 
JW605, JW620-JW621, and JW695-JW696 into pDB114 respectively. To make 1048 
pAV158, pAV159, pAV162, pAV164, and pAV165, one piece Gibson assembly was 1049 
performed using H235-H236 to remove cas9 from pAV149, pAV150, pAV153, pAV155, 1050 
and pDB114, respectively. To transfer high and low-transducing spacers to a pE19458 1051 
background, a two-piece Gibson assembly was used. AV176 and AV177 were used to 1052 
amplify pE194 and AV423-AV424 were used to amplify the tracrRNA, cas9, and 1053 
CRISPR array cassette. pAV149, pAV150, pAV153, and pAV155 were used as 1054 
templates for pAV175, pAV173, pAV174, and pAV176, respectively. To make pAV185, 1055 
the last 10-basepairs of H1 were complemented. BsaI cloning was used to insert 1056 
annealed oligonucleotides AV485-AV486 into pDB114. pAV195 was made with a one-1057 
piece Gibson assembly, where pAV185 was amplified with H235-H236 to remove cas9. 1058 
To create phage 8530 editing plasmid pAV247 a three-piece Gibson was performed 1059 
where pC19451 was amplified with AV186-AV204, and phage homology arms were 1060 
amplified AV607-AV611 and AV609-AV610. To create the construct to tag the type III-A 1061 
locus with erythromycin a two-piece Gibson assembly was performed, where pTM40262 1062 
was amplified with AV590-AV591 and the homology arm was amplified with AV622-1063 
AV623 from 08BA02176 and grown in strain TM1762. To create phage 85 editing 1064 
plasmid pAV281 a three-piece Gibson was performed where pC194 was amplified with 1065 
AV186-AV204, and phage homology arms were amplified AV862-AV864 and AV863-1066 
AV865. To add a spacer that target phage 85 (5’- 1067 
TTTCAACATTCTTCAACATACGCTGTCCTTGTGAGT-3’) to 08BA02176, pAV282 was 1068 
made with a 3-piece Gibson assembly, where pTM402 was amplified with AV590-1069 
AV591, and homology arms were amplified with AV879-AV880 and AV878-AV881. 1070 
pAV282 was grown in TM17. To make phage 85 portal-targeting plasmid pAV284, BsaI 1071 
cloning was used to insert AV866-AV867 into pDB114.  1072 
  
Table S1. Strains used in this study. 1073 
Strains Description Reference 
RN4220 S. aureus strain  50 
OS2 Chromosomal erythromycin resistance RN4220  52 
08BA02176 S. aureus MRSA with CRISPR type III-A 29 
DGCC7710 S. thermophilus strain 1 
PA14 P. aeruginosa strain 63 
PA14--SM P. aeruginosa strain streptomycin tagged type I-F This study 
JW263 Chromosomal kanamycin resistance RN4220  34 
JAV9 reca- RN4220 This study 
JAV21 Chromosomal erythromycin and kanamycin RN4220 This study 
JAV27 CRISPR1 and CRISPR3 knockout DGC7710 This study 
JAV28 Erythromycin CRISPR1 tag DGC7710 This study 
JAV33 Erythromycin CRISPR1 tag BIM DGC7710 This study 
JAV29 Erythromycin type III-A tag 08BA02176 This study 
JAV32 Erythromycin type III-A tag and  85 spacer 08BA02176 This study 
JAV33 RN4220  ΦNM4γ4 insensitive mutant This study 
pWJ40 S. pyogenes type II-A CRISPR system on pC194 32 
pWJ244 E. coli ColE1 vector for genome engineering 34 
pWJ326 S. aureus temperature-sensitive phagemid 34 
pC194 Chloramphenicol-resistant S. aureus plasmid  51 
pE194 Erythromycin-resistant S. aureus plasmid 58 
pT181 Tetracycline-resistant S. aureus plasmid 64 
pLZ12spec Spectinomycin resistant cloning vector 57 
TM17 Chromosomal expression of pT181 repC 62 
pTM402 pT181 ds repC- cop 623 replication origin 62 
pBAM1-Sm Streptomycin resistance cassette 56 
pHERD30T E. coli/P. aeruginosa shuttle vector 65 
pGG12 Type III-A DUF1318 targeting plasmid on pC194 55 
pDB114 Control spacer with cas9  61 
pAV44 recA deletion allelic exchange vector on ColE1 vector This study 
pAV149 High-transducing spacer 1 (H1) with cas9 on pC194  This study 
pAV150 Low-transducing spacer 2 (L) with cas9 on pC194  This study 
pAV153 Intermediate-transducing spacer (I) with cas9 on pC194  This study 
pAV155 High-transducing spacer 2 (H2) with cas9 on pC194  This study 
pAV158 H1, no cas9 on pC194  This study 
pAV159 L, no cas9 on pC194  This study 
pAV162 I, no cas9 on pC194  This study 
pAV164 H2, no cas9 on pC194  This study 
pAV165 Control spacer with no cas9 on pE194 This study 
pAV173 L with cas9 on pE194  This study 
pAV174 I with cas9 on pE194  This study 
pAV175 H1 with cas9 on pE194  This study 
pAV176 H2 with cas9 on pE194  This study 
pAV185 H1 Truncation with cas9 on pC194 This study 
pAV195 H1 Truncation with no cas9 on pC194 This study 
pAV247 85α2 editing to add 08BA02176 spacer 1 target site on pC194 This study 
pAV253 Erythromycin type III-A tag on pTM401 This study 
pAV281 85α3 editing to add 08BA02176 spacer 1 target site on pC194 This study 
pAV282 Erythromycin type III-A and 85 spacer on pTM401 This study 
pAV284 85α3 portal protein targeting spacer on pDB114 This study 
pAV293 P51-like targeting Φ12γ3 spacer on pDB114 This study 
pAV294 dUTPase targeting Φ12γ3 spacer on pDB114 This study 
pAV295 HNH targeting Φ12γ3 spacer on pDB114 This study 
pAV296 Hydrolase  targeting Φ12γ3 spacer on pDB114 This study 
ΦNM4γ4 Virulent S. aureus pac phage 32 
Φ12γ3 Virulent S. aureus cos phage 34 
85 S. aureus phage 30 
85α1 S. aureus phage variant infects 08BA02176 This study 
85α2 85α1 targeted early-genome by spacer 1 08BA02176 This study 
85α4 85α1 targeted mid-genome by spacer 1 08BA02176 This study 
2972 Virulent S. thermophilus phage 66 
2972α1 2972 JAV33 PAM escaper phage This study 
  
  1074 DMS3vir Virulent P. aeruginosa mu-like phage 54 
  
Table S2. DNA oligonucleotides used in this study. 1075 
Primer 
Name 
Sequence (5'-3') 
AV122 GCTTTTTCTAAATGTTTTTTAAGTAAATCAAGTAC 
AV176 GAGTGATCGTTAAATTTATACTGCAATCGG 
AV177 CATGTTCATATTTATCAGAGCTCGTGC 
AV186 AATCGATAACCACATAACAGTCATAAAAC 
AV204 ATAGGTATGTGGTTTTGTATTGGAAT 
AV206 TAATGACTTTGGTGCATCTAAAGCTTTTTGACGATCGTTATC 
AV207 CAAAAAGCTTTAGATGCACCAAAGTCATTATTTGACGAA 
AV208 ATATTTTAAAAATATCCCACGTGGCCCAGATTGTTGGTAAAG 
AV209 CGAGGCCCTTTCGTCTTCACGATGTTTCGTCCTTCTCGTCC 
AV223 CGCTAATACCAACGGACAATTTC 
AV224 CCAGCTCGTTTCGCTAATGTC 
AV404(a) aaacGTTAGCAGTATTTGGAGCACTGTTACAAGTG 
AV405(a) aaaacACTTGTAACAGTGCTCCAAATACTGCTAAC 
AV406(a) aaacTCTATGTCTTCTAAATTCAGTGATGTATTCG 
AV407(a) aaaacGAATACATCACTGAATTTAGAAGACATAGA 
AV412(a) aaacATATTCATCAGATTCCAATACTACGTTAATG 
AV413(a) aaaacATTAACGTAGTATTGGAATCTGATGAATAT 
AV416(a) aaacTAAGTAAAAAGCTAAATGAAGATAGTTCTTG 
AV417(a) aaaacAAGAACTATCTTCATTTAGCTTTTTACTTA 
AV423 TGATAAATATGAACATGGGATTCTGTGATTTGGATCCTTCC 
AV424 AAATTTAACGATCACTCCCCACTTTATCCAATTTTCGTTTG 
AV437 TAATACGACTCACTATAGGGTTTGGAGCACTGTTACAAGTGTTTTAGAGCTATGCTGTT 
AV438 AACAGCATAGCTCTAAAACACTTGTAACAGTGCTCCAAACCCTATAGTGAGTCGTATTA 
AV439 TAATACGACTCACTATAGGGCTAAATTCAGTGATGTATTCGTTTTAGAGCTATGCTGTT 
AV440 AACAGCATAGCTCTAAAACGAATACATCACTGAATTTAGCCCTATAGTGAGTCGTATTA 
AV456 CAACCGTACTTGTAAGTACACTTG 
AV457 CATCGCTAGTCATGTGTCTGTC 
AV458 GGTGTTTGACGAGATTAAGTCACG 
AV459 GTCTGTTGTCCATCAAAATCACC 
AV469 GCAGTAGTTGCAGTCATTGGTG 
AV471 CTGATAGATTGCCTACAAACGAAGG 
AV485(a) aaacCAATCGTCATTTTGGAGCACTGTTACAAGTG 
AV486(a) aaaacACTTGTAACAGTGCTCCAAAATGACGATTG 
AV523 CCCTTTAGTAACGTGTAACTTTCC 
AV525 CTACATTACGCATTTGGAATACCAAC 
AV547 CTCGACGACCAAGATGTTGAGG 
AV590 TGTACTTTTTACAGTCGGGAATGGCATGCCGAATTGGG 
AV591 GACTGTATACCTTCCGAGCCGCGGTTAGAAAGGGCTTGA 
AV594 GTCTAGAGACCGGGGACTTATC 
AV607 ATACAAAACCACATACCTATGGGATAGGTATTGCAAGAGCGTTG 
AV609 CTGTTATGTGGTTATCGATTCTCCTCTAGCTGTTCTAGTTAGCC 
AV610 GGTATCGGAATTAATGAACTTATAGACAGTTGTTGAGGCAGAGAGTAAAG 
AV611 CATTAATTCCGATACCTAGATTATCTCGTCCTGTTGAATCTTTGAATGTTG 
AV622 CTCGGAAGGTATACAGTCCACTTTTACCACTTTTTTAGAGTGAC 
AV623 GACTGTAAAAAGTACAGCTAAAATGCGCGTAGCTG 
AV638 TGCTGAGACAACCTAGTCTCTC 
AV648 TCAATCGATACATCACGAGAGGC 
AV664 CTTGGGCAGAAAACCTTGTAGATG 
AV665 AGTCACGTTACGTTATGAACTTGGCTTTTTAAAATACACG 
AV666 ACCCTTGGACTTTCGTCACTACTAACTTGTTGGCAAGG 
AV667 CAAGGGCGATGACCTTCAAGG 
AV668 CTCTTAATTCATCAGGTGACCCTG 
AV669 TTTTAAAAATATCCCACCTCTACTATTTTCCCACCTCATCC 
AV673 GACGAAAGTCCAAGGGTTTATTG 
AV672 ATAACGTAACGTGACTGGCAAGA 
AV682  ACTTTTTACAGTCGGTTGTTATCACAATTTTCGGTTGACATC 
AV683 CTCATAGGTGTCATCCCATTTTCC 
AV692 TGATAAATATGAACATGCTAACTTGTTGGCAAGGAAATCGG 
AV693 ATGCATAAACTGCATCCTAGTTTAAAATCATTTGTTCAAAAATAAAATCC 
AV694 GCCTGATAAGGTGTTCGTTGTC 
  
AV695 GGATGCAGTTTATGCATCCCTTAAC 
AV724 GAATCTTGATTTGCTGTCAAACAG 
AV812 GGTGGAGATTTCTACTTACGTGGC 
AV862 CATTAATTCCGATACCTAGATTATCTGGCAATTACAATCATTCCTTTTTATCAAC 
AV863 GGTATCGGAATTAATGAACTTATAGATAACAAAAACACTCAAGAATATTGGGAAG 
AV864 ATACAAAACCACATACCTATGAAGCTCACACCACGTGAAAAC 
AV865 CTGTTATGTGGTTATCGATTCTTCCGGTGAAATTTCTTTCATGC 
AV866(a) aaacTTCTTCCCAATATTCTTGAGTGTTTTTGTTg 
AV867(a) aaaacAACAAAAACACTCAAGAATATTGGGAAGAA 
AV868 CATAGAAAAATACGGTTCTCAAGGAAG 
AV869 CTACGGATTGAAGAACGGTTTAGC 
AV876 CCAAGACCCTGAATTGGAAGTC 
AV877 GCATTGATTTCTTTTTCAATGCGC 
AV878 GCTGTCCTTGTGAGTGATCGATAACTACCCCGAATAACAGGGGACGAGAATTCTATA 
AV879 CACTCACAAGGACAGCGTATGTTGAAGAATGTTGAAAATTCTCGTCCCCTGTTATTC 
AV880 GCTCGGAAGGTATACAGTCGAATAATGGCTCTATTACAACGGTAC 
AV881 CACTCTCGGACAATACTCCATCCCCTAAAAATTAATCAATGCG 
H235 GATATCGGCACAAATAGCTTAGATGCCACTCTTATCCATCAATCC 
H236 AAGAGTGGCATCTAAGCTATTTGTGCCGATATCTAAGCC 
H50 AAAACAAAAAGCGCAAGAAGAAATCAACCAGCGCA 
oGG38 AAGATAAAGAATTTGCTCAAGACG 
oGG40 ACCATTAAAACTCGTCATTCTTTC 
oGG50 GTTAATGTTACGAATGATGAACC 
oGG96 AAGATGCAACAATGGGAACCAAG 
JM117 GTTTGAACTCAACAAGTCTCAGTGTGCTG 
JW96 AAAACAAAGCTGAAATTGAAGGAGAAATGGGAGAC 
JW600(a) aaacCAAAAGCAGTCCGAGACAGGTTAGTTGAAGg 
JW601(a) aaaacCTTCAACTAACCTGTCTCGGACTGCTTTTG 
JW604(a) aaacCGGAGTGTAAAGACATCTTAGATCGAGTTAg 
JW605(a) aaaacTAACTCGATCTAAGATGTCTTTACACTCCG 
JW620(a) aaacTGGAAGAAGTTAAGAGAGATAGCATTAGATg 
JW621(a) aaaacATCTAATGCTATCTCTCTTAACTTCTTCCA 
JW655 ACACTAAGCAGTGCGATTACAAAATTTTTTAGAC 
JW656 GTACGTCGCTAGTGCGATTACAAAATTTTTTAGAC 
JW657 AGAAGTGCGATTACAAAATTTTTTAGAC 
JW658 CTACAGTGCGATTACAAAATTTTTTAGAC 
JW659 TGAAGAGTGCGATTACAAAATTTTTTAGAC 
JW660 CGCATTAGTGCGATTACAAAATTTTTTAGAC 
JW661 TACACGGAGTGCGATTACAAAATTTTTTAGAC 
JW662 CATAAGTAAGTGCGATTACAAAATTTTTTAGAC 
JW695(a) aaacGAGCGCTAATCTAAACACTTTCACATCGTTg 
JW696(a) aaaacAACGATGTGAAAGTGTTTAGATTAGCGCTC 
L400 CGAAATTTTTTAGACAAAAATAGTC 
W964 TCGTCAAATAATGACTTTGGTGC 
W1005 GTGAAGACGAAAGGGCCTCGTG 
W1055 GTGGGATATTTTTAAAATATATATTTATG 
W1055 GTGGGATATTTTTAAAATATATATTTATG 
W1056 AACCGACTGTAAAAAGTACAGTCG 
NP255 AAAACCTTTTTCTTCAATTGGTCGACGTTTGAATAT 
pB_Sm_F CCGGCCGGATCCTGGGGTACAGTCTATGCCTCGG 
pB_Sm_R CCGGCCGGATCCGACAATTGTCTTATTTGCCGAC 
FL1_F ACCAGATCCTGCCGCAGTACTGG 
FL1_R CCGCCAATTGCCCGAAGCTTCCG 
FL2_F GCCGTTCGGGCGCGAAAGGTCT 
FL2_R ACCCCGAGGTAACAGAATCGTC 
crRNA _F GTTTCGCGAGGACCGGGACGGCGATCAACCGT 
crRNA_R ACGGTTGATCGCCGTCCCGGTCCTCGCGAAAC 
CR2_F GCTCGACTACTACAACGTCCGGC 
CR2_R GGGTTTCTGGCGGGAAAAACTCG 
(a)lower case sequences are compatible with the overhangs of BsaI cleavage of the CRISPR  1076 
      repeat, and are required for spacer cloning. 1077 
1078 
  
Supplementary Figures 1079 
 1080 
Fig. S1. Spacer-mediated transduction of chromosomal loci. (A) Phage 1081 
recombination with a CRISPR-Cas locus on a linear element. Following recombination 1082 
between the spacer and the phage genome, phage packaging machinery preferentially 1083 
packages the phage-linked locus. In the case of CRISPR locus transduction, upon 1084 
injection into the recipient cell the element only has homology for a single crossover 1085 
event (solid lines), while lacking homology for the second crossover (dotted lines). (B) 1086 
Transducing particle production from P. aeruginosa. Overnight cultures (+cells) 1087 
containing the wild type array (crt) or a phage-targeting spacer (trgt) were infected on 1088 
soft agar plates with a non-targeted, PAM-escaper phage. Plates without cells were 1089 
used as a control (-cells). 24 hours post-infection phage was harvested and transducing 1090 
phage particles were determined by infecting a CRISPR- culture and plating on soft 1091 
agar lawns with antibiotic selection for recipient cells. CRISPR transduction was 1092 
confirmed by PCR. Mean + STD of 3 (-cell) or 8 biological replicates (+cells) are 1093 
reported. (C) Transducing particle production from S. thermophilus. Liquid cultures 1094 
containing the wild type array (crt) or a phage-targeting spacer (trgt) were infected with 1095 
a non-targeted phage that escaped CRISPR1 immunity through a PAM mutation. Three 1096 
hours post-infection phage was harvested and transducing phage particles were 1097 
determined by infecting a CRISPR- culture at an MOI of 1 and plating for antibiotic 1098 
resistance. CRISPR transduction was confirmed by PCR. Mean + STD of 3 biological 1099 
replicates are reported. (D) Transduction recipient cells from Fig. 1B were taken 1100 
following phage infection and subsequent incubation and plated to count colonies to 1101 
determine cell viability. Mean + STD of 3 biological replicates are reported.  1102 
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 1103 
Fig. S2. Adaptation of transduced CRISPR-Cas loci and transduction of 1104 
chromosomal resistance markers. (A) Organization of S. pyogenes CRISPR-Cas 1105 
locus. Arrows indicated annealing positions of primers used to detect expansion of 1106 
CRISPR array (B) PCR-based analysis to check for spacer acquisition in transduced 1107 
colonies obtained in Fig. 1D. Labels indicate time point of transducing phage collection. 1108 
Positive adaptation control of a single spacer acquisition indicated by +, while non-1109 
adapted control represented by (-). (C) Cultures without CRISPR-Cas loci infected at an 1110 
MOI of 1 by ΦNM4γ4 collected from CRISPR+ containing cultures at indicated time 1111 
points from Fig. 1D. Cultures were plated 16 hours post infection and colonies were 1112 
counted to determine overall phage resistance and also counted on plates with 1113 
antibiotics selecting for the CRISPR-Cas locus to determine transduction levels. Limit of 1114 
detection is 100 cfu/ml. Mean + STD of 3 biological replicates are reported. (D) PCR-1115 
based analysis to check for spacer acquisition in transduced colonies collected in Fig. 1116 
1D at 18 hours post infection. Labels indicate transduced colonies collected from each 1117 
replicate. Non-adapted control is also shown (-). (E) Restriction enzyme digest of 1118 
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CRISPR-Cas plasmids in transduced colonies collected in Fig. 1D at 18 hours post 1119 
infection. Plasmids are digested with HindIII. Labels indicate transduced colonies 1120 
collected from each replicate. Non-adapted control is also shown. (F) Transduction of 1121 
either the chromosomal erythromycin resistance (ErmR) or both chromosomal 1122 
erythromycin and kanamycin resistance (ErmR, KanR) following infection by ΦNM4γ4. 1123 
Cultures harboring ErmR and KanR chromosomal markers were infected with ΦNM4γ4 1124 
at a MOI of 1 and phage was collected 2 hours post infection. Levels of transduction 1125 
were determined by infecting a susceptible culture at a MOI of 1 for 20 minutes, 1126 
washing cells, and plating for antibiotic resistance. Limit of detection is 1.5 cfu/ml 1127 
(dotted line). Mean + STD of 3 biological replicates are reported.  1128 
  
 1129 
Fig. S3. Adapted and transduced spacer frequencies possess distinct profiles. (A) 1130 
The average frequency of CRISPR-transduced reads plotted against the 4 individual 1131 
replicates of CRISPR-transduced reads (#1-4). Each point represents a single spacer 1132 
and its representation in sequenced populations. (B) The average frequency of 1133 
CRISPR-resistant reads plotted against the 4 individual replicates of CRISPR-1134 
transduced reads (#1-4). Each point represents a single spacer and its representation in 1135 
sequenced populations. (C) Data as described in Figure 2A, with each replicate mapped 1136 
against the ΦNM4γ4 genome and plotted individually. Solid lines represent CRISPR-1137 
resistant replicates and dashed lines are CRISPR-transduced replicates.  1138 
A
102
103
104
105
106
C
R
IS
P
R
-t
ra
n
s
d
u
c
e
d
 (
R
P
M
)
101
#1
100
10-1
CRISPR-transduced average (RPM)
#2
#3
#4
102 103 104 105 10610110010-1
B
#1
#2
#3
#4
102
103
104
105
106
C
R
IS
P
R
-t
ra
n
s
d
u
c
e
d
 (
R
P
M
)
101
100
10-1
CRISPR-resistant average (RPM)
10410-1
Resistant-1
Resistant-2
Resistant-3
Resistant-4
Transduced-1
Transduced-2
Transduced-3
Transduced-4
0 10 20 30 40
ΦNM4γ4 genome position (Kb)
102
103
104
105
106
R
P
M
101
C
102 103101100 105
  
 1139 
Fig. S4. Phage recombination with CRISPR spacers enhance transduction 1140 
independent of RecA and in cos-phages. (A) PCR loading controls from 1141 
phage/CRISPR-Cas locus recombinants. Cells containing just the CRISPR array (-1142 
Cas9) or Cas9 and the CRISPR array (+Cas9) or were infected at a MOI of 1 and 50, 1143 
respectively. 30 minutes post infection for –Cas9 strains or 60 minutes post infection for 1144 
+Cas9 strains, genomic DNA was extracted from the cellular pellet (cell DNA). For all 1145 
strains, 60 minutes post infection DNA was also extracted from filtered supernatant 1146 
(phage DNA). Primers annealing to phage locus gp14 and chromosomal locus recA 1147 
were used to determine DNA levels. (B) Deep sequencing of phage DNA harvested 1148 
from cells containing Cas9 and spacer H1. Cultures were infected with ΦNM4γ4 at a 1149 
MOI of 50 and phages were collected 90 minutes post infection. Phage DNA was 1150 
subject to deep sequencing and aligned to 300 basepairs of the phage CRISPR locus 1151 
junction that contains the PAM. Each point on the graph represents the number of reads 1152 
that originate at that nucleotide position and have full coverage to the right for the 75-1153 
nucleotide deep sequencing read. Dotted lines indicate portion of reads that map to the 1154 
CRISPR locus and ΦNM4γ4.  1155 
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Fig. S5. CRISPR escaper levels do not affect transduction of CRISPR-Cas loci. (A) 1157 
ΦNM4γ4 plaquing efficiency on soft agar lawns of high, intermediate, and low-1158 
transduced spacers (H1, H2, I, L) compared to a non-targeting spacer control (ctl). 1159 
Mean + STD of 3 biological replicates are reported. (B) ΦNM4γ4 plaquing efficiency on 1160 
soft agar lawns of individual spacers or combined spacers (H1+H2) expressed from 1161 
different plasmids. Limit of detection is 1*10-9 pfu/ml. Mean + STD of 3 biological 1162 
replicates are reported. (C) Transducing immune particle production from spacers 1163 
combined with a second plasmid containing the spacer as indicated. The transduction 1164 
efficiency of plasmid 2 is quantified. Cultures were infected with ΦNM4γ4 at a MOI of 50 1165 
and phages were collected 90 minutes post infection. Levels of transducing-immune 1166 
phage particles were determined by infecting a susceptible culture at a MOI of 1 and 1167 
plating on soft agar lawns with antibiotic selection for recipient cells and the antibiotic 1168 
resistance cassette on the CRISPR plasmid. Data condensed from (Fig. 4C). Limit of 1169 
detection is 1.5 cfu/ml (dotted line). Mean + STD of 3 biological replicates are reported.  1170 
  
  1171 
Fig. S6. Spacer sequences dispensable for targeting enhance transduction. (A) 1172 
Schematic of CRISPR DNA locus and mature crRNA for full-length H1 (30 nt) or 1173 
truncated H1 (20 nt), containing 10 mismatches in the 5’ end of the spacer (B) Growth 1174 
of H1 (30 nt) or H1 (20 nt) following infection. Strains were infected with ΦNM4γ4 at an 1175 
MOI of 1. For samples denoted with an asterisk, simulation of CRISPR adaptation was 1176 
performed by using cells lacking CRISPR to dilute immune culture 1:10,000. Growth 1177 
was determined by optical density measured at 600nm (OD600) and compared to a 1178 
uninfected control (no phage). Mean -STD of 3 biological replicates are reported. (C) 1179 
Transduction of plasmids containing just the CRISPR array with either a control spacer 1180 
(ctl) or targeting spacers from (A). Cultures were infected with ΦNM4γ4 at a MOI of 1 1181 
and phage was collected 2 hours post infection. Levels of transduction were determined 1182 
by infecting a susceptible culture at a MOI of 1 for 20 minutes, washing cells, and 1183 
plating for the antibiotic resistance of the plasmid. Mean + STD of 3 biological replicates 1184 
are reported. (D) Transducing-immune particles produced by strains from (A) and strain 1185 
with low transducing characteristics (L). Cultures were infected with ΦNM4γ4 at a MOI 1186 
of 50 and phages were collected 90 minutes post infection. Levels of transducing-1187 
  
immune phage particles were determined by infecting a susceptible culture at a MOI of 1188 
1 and plating on soft agar lawns with antibiotic selection for recipient cells and the 1189 
antibiotic resistance cassette on the CRISPR plasmid. Mean + STD of 3 biological 1190 
replicates are reported. 1191 
Extended Data File 1 (separate file) 1192 
Deep sequencing raw data used to generate figures 2A, S2A, S2B, and S2C. 1193 
